Cohort Description of Younger With AV-block

Genetic Disease Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03024047
• Other study ID #: DAN-BLOCK_Study1
• Status: Not yet recruiting
• Phase: N/A
• First received: January 4, 2017
• Last updated: January 13, 2017
• Start date: January 2017

Study information

• Verified date: January 2017
• Source: University of Aarhus
• Contact: Johnni T. R. Dideriksen, M.D.
• Phone: 0045 40832508
• Email: johndide[@]rm.dk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

Disturbances of the heart's atrioventricular conduction - AV-block - may show by shortness of breath, fainting or sudden death. If AV-block is diagnosed in time pacemaker therapy may be lifesaving.

AV-block in younger can be seen along with structural or ischemic heart disease, congenital heart disease (incl. congenital AV-block) storage disorders, specific muscle diseases, sarcoidosis, Borrelia infection or drug intoxication. AV-block in younger can also be seen in conditions, primarily localized to the AV-node without other cardiac disease at diagnosis.

This form of AV-block is often hereditary and can be seen in families where relatives have another types of heart disease in form of fore example, cardiomyopathy, ion channel disease or sudden death. The different forms of presentation are due to the same gene mutation being expressed differently within the same family. Thus, early onset of AV-block (<50 years) may indicate hereditary AV-conduction disorder but it can also be the first manifestation of severe ion channel disease or cardiomyopathy.

Denmark has annually over 50 individuals <50 years treated with pacemaker due to advanced AV-block. There have been no overall figures regarding the causes of advanced AV-block, and therefore no systematic approach to diagnosing this group of patients. Furthermore, the prevalence of individuals with a genetic cause of AV-block is unknown and presumably an often overlooked diagnosis among younger patients with advanced AV-blok. There are no data on disease progression after diagnosis, and therefore there is no evidence-based knowledge about how these patients should be followed after diagnosis.

With modern gene technology, a range of new, yet unknown genes with potentially pathogenic mutations is likely to be identified. Identification of such genes, and the development of a strategy for systematic approach to diagnose younger patients with AV-block, will enable presymptomatic genetic screening of relatives and implementation of evidence-based, preventive treatment with pacemaker and/or medical treatment for heart failure based on a specific genetic predisposition for development of AV-block with or without heart failure.

Hypotheses:

In a significant proportion of younger patients with advanced AV-block the underlying cause is unknown.

Objective:

To investigate the prevalence and causes of advanced AV-block in younger patients in Denmark and describe the current diagnostics.

Method:

The study is a cross sectional study. The patients for this study are identified from Danish Pacemaker and ICD Register. The investigators will review medical records and obtain clinical information and test results (see detailed description).

Perspectives:

This study is the first part of a large study of AV-block in younger patients in Denmark. The overall goal, is to increase knowledge about the causes of and disease progression after the diagnosis of advanced AV-block in young patients which could lead to a significant improvement in the treatment of this patient group and may lead to a customized choice of pacemaker type in the future and perhaps additional medical treatment in this patient group. This could potentially lead to a reduction in both their morbidity mortality.

Description:

Method:

The following covariates will be reported.

Date of diagnosis of AV-block:

The date of diagnosis is defined as the day the physician diagnoses the AV-block. E.g. if the patient has a Holter monitoring performed, the date of diagnosis is the dag the monitoring is reviewed.

Reported as: Day-month-year

Comorbidity at day of first pacemaker implant:

Registered as one or more of the following:

1. Diabetes

2. Hypertension

3. Hypercholesterolemia

4. Heart failure

5. Atrial fibrillation or flutter

6. Ischemic heart disease

7. Sarcoidosis

8. Connecting tissue disorder

9. Other

Smoking status at day of first pacemaker implant:

Registered as: Current, former, never

Device selected at first pacemaker implant:

Registered as: DDD, CTR, etcetera

Genetic investigation:

Is there performed genetic investigation due to the finding of AV-block? Investigation must be initiated maximum 4 weeks after day of first pacemaker implant.

Registered as: y/n.

Date of first pacemaker implant:

Registered as: Day-month-year

Implant sight

ECG 12 description:

ECG 12 must be taken maximum one week before day of first pacemaker implant Registered as:

Bpm., RBBB y/n, LBBB y/n, PR in msec, QRS in msec, QT in msec, QTc in msec (Frederica)

Implant indication:

Registered as one of following:

1. First-degree atrioventricular block with symptoms

2. Mobitz type 1 with symptoms

3. Mobitz type 2

4. Advanced second-degree atrioventricular block

5. Third-degree atrioventricular block

6. Unknown The most malignant is chosen and it is reported if it is intermittent or persistent.

Symptoms:

Registered as one or more of following:

1. Dyspnoea

2. Fatigue

3. Malaise

4. Dizziness

5. Syncope

6. Angina

7. Cardiac arrest

8. No symptoms

Echocardiography:

Performed maximum two weeks before day of first pacemaker implant The reported values are what the echocardiographer describes.

Registered as:

LVEF in % (values over 60% is reported as >60 %) Hypertrophy of LV y/n Dilatation of LV y/n Dilatation of LA y/n Valvular disease/artificial valve y/n

Coronary angiography:

At day of first pacemaker implant +/- 4 weeks

Registered as:

Normal y/n Significantly disease on LAD y/n Significantly disease on RCA y/n Significantly disease on CX y/n Significantly disease = leading to CABG, PCI or antithrombotic treatment

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1255
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 49 Years

Eligibility

Inclusion Criteria:

• All patients in Denmark

• Treated with pacemaker due to AV-block

• Implanted for the first time between 01.01.1996 - 31.12.2015

• Age at implantation <50 years

Exclusion Criteria:

• Non

Related Conditions & MeSH terms

• Arrhythmias, Cardiac
• Atrioventricular Block
• Bundle-Branch Block
• Genetic Disease
• Heart Block
• Progressive Cardiac Conduction Defect

Intervention

Device:
• Pacemaker

Locations

Country	Name	City	State
Denmark	Department of cardiology, Research, Aarhus University Hospital, Denmark	Aarhus

Sponsors (1)

Lead Sponsor	Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of structural heart disease as cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of ischemic heart disease as cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of congenital heart disease as cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of congenital AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of muscular dystrophy as cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of sarcoidosis as cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of lyme disease as cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of genetic cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of complications to operation as cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of complications to radio frequency ablation as cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of endocarditis as cause of AV-block		01.01.1996 - 31.12.2015
Primary	Prevalence of unknown cause of AV-block		01.01.1996 - 31.12.2015